Rob Dickey brings extensive financial experience and expertise to Cell One Partners, enhancing the firm's ability to provide deeply grounded strategic consulting for cell and gene therapy companies.  Rob’s experience includes over 25 years in CFO and Board member roles for biotech and medical device companies, both private and public, in all stages of development with expertise in fundraising, M&A, partnering/licensing transactions, project management, as well as building organizations and interacting with Boards, VC’s, shareholders and Wall Street. He raised over $100 million in private company financing, over $200 million for public companies, and over $1 billion when he was an investment banker.  He has international experience including equity fundraising on the London Exchange, a joint venture in India; stock repurchase in Taiwan; and research collaborations and M&A with Japanese companies and played key roles in negotiating/monitoring collaborations with Academia Sinica (Taiwan), Amgen, Dow, Memorial Sloan Kettering, Ono Pharmaceuticals (Japan), Rutgers, University of Pennsylvania and Weill Cornell.  His previous 18-year tenure in investment banking, including 14 years at Lehman Brothers, was directed at M&A and public and private capital markets transactions.

​

As part of Cell One Partners' leadership team, Rob Dickey contributes to delivering comprehensive solutions that link scientific innovation and commercialization strategies with financial perspective. His unique blend of life sciences knowledge and financial expertise makes him a valuable asset in guiding companies through the intricate landscape of cell and gene therapy development.